UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'

Nature reviews. Microbiology, 2004-04, Vol.2 (4), p.289-300

Drusano, George L

2004

Volltextzugriff (PDF)

Relationship between Initial Vancomycin Concentration-Time Profile and Nephrotoxicity among Hospitalized Patients

Clinical infectious diseases, 2009-08, Vol.49 (4), p.507-514

2009

Volltextzugriff (PDF)

Are Vancomycin Trough Concentrations Adequate for Optimal Dosing?

Antimicrobial Agents and Chemotherapy, 2014-01, Vol.58 (1), p.309-316

2014

Volltextzugriff (PDF)

Dosing Regimen Matters: the Importance of Early Intervention and Rapid Attainment of the Pharmacokinetic/Pharmacodynamic Target

Antimicrobial Agents and Chemotherapy, 2012-06, Vol.56 (6), p.2795-2805

2012

Volltextzugriff (PDF)

Piperacillin-Tazobactam for Pseudomonas aeruginosa Infection: Clinical Implications of an Extended-Infusion Dosing Strategy

Clinical infectious diseases, 2007-02, Vol.44 (3), p.357-363

2007

Volltextzugriff (PDF)

Rational design of a new antibiotic class for drug-resistant infections

Nature (London), 2021-09, Vol.597 (7878), p.698-702

2021

Volltextzugriff (PDF)

Pharmacokinetics-Pharmacodynamics of Antimicrobial Therapy: It's Not Just for Mice Anymore

Clinical infectious diseases, 2007-01, Vol.44 (1), p.79-86

2007

Volltextzugriff (PDF)

Daptomycin Exposure and the Probability of Elevations in the Creatine Phosphokinase Level: Data from a Randomized Trial of Patients with Bacteremia and Endocarditis

Clinical infectious diseases, 2010-06, Vol.50 (12), p.1568-1574

2010

Volltextzugriff (PDF)

Analysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculosis

PloS one, 2014-07, Vol.9 (7), p.e101311

2014

Volltextzugriff (PDF)

Why Molnupiravir Fails in Hospitalized Patients

mBio, 2022-12, Vol.13 (6), p.e0291622

2022

Volltextzugriff (PDF)

Polymyxin Susceptibility Testing and Interpretive Breakpoints: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST)

Antimicrobial agents and chemotherapy, 2020-01, Vol.64 (2)

2020

Volltextzugriff (PDF)

Concentration-Dependent Mycobacterium tuberculosis Killing and Prevention of Resistance by Rifampin

Antimicrobial Agents and Chemotherapy, 2007-11, Vol.51 (11), p.3781-3788

2007

Volltextzugriff (PDF)

Back to the Future: Using Aminoglycosides Again and How to Dose Them Optimally

Clinical infectious diseases, 2007-09, Vol.45 (6), p.753-760

2007

Volltextzugriff (PDF)

Conserving antibiotics for the future: New ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective

Drug resistance updates, 2011-04, Vol.14 (2), p.107-117

2011

Volltextzugriff (PDF)

Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update

Journal of antimicrobial chemotherapy, 2005-05, Vol.55 (5), p.601-607

2005

Volltextzugriff (PDF)

L-Thyroxine vs. 3,5,3'-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase

American Journal of Physiology: Cell Physiology, 2009-05, Vol.296 (5), p.C980-C991

2009

Volltextzugriff (PDF)

Selection of a Moxifloxacin Dose That Suppresses Drug Resistance in Mycobacterium tuberculosis, by Use of an In Vitro Pharmacodynamic Infection Model and Mathematical Modeling

The Journal of infectious diseases, 2004-11, Vol.190 (9), p.1642-1651

2004

Volltextzugriff (PDF)

Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit Considerations

Antimicrobial agents and chemotherapy, 2016-03, Vol.60 (3), p.1600-1607

2016

Volltextzugriff (PDF)

Pharmacodynamics of Caspofungin in a Murine Model of Systemic Candidiasis: Importance of Persistence of Caspofungin in Tissues to Understanding Drug Activity

Antimicrobial Agents and Chemotherapy, 2005-12, Vol.49 (12), p.5058-5068

2005

Volltextzugriff (PDF)

Pharmacokinetic-Pharmacodynamic Considerations in the Design of Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia Studies: Look before You Leap

Clinical infectious diseases, 2010-08, Vol.51 (Supplement-1), p.S103-S110

2010

Volltextzugriff (PDF)

Quinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae

Antimicrobial agents and chemotherapy, 2006, Vol.50 (1), p.310-317

2006

Volltextzugriff (PDF)

Combination Therapy with UV-4B and Molnupiravir Enhances SARS-CoV-2 Suppression

Viruses, 2023-05, Vol.15 (5), p.1175

2023

Volltextzugriff (PDF)

Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy

mBio, 2015-11, Vol.6 (6), p.e01741-e01715

2015

Volltextzugriff (PDF)

Relationship between Fluoroquinolone Area under the Curve:Minimum Inhibitory Concentration Ratio and the Probability of Eradication of the Infecting Pathogen, in Patients with Nosocomial Pneumonia

The Journal of infectious diseases, 2004-05, Vol.189 (9), p.1590-1597

2004

Volltextzugriff (PDF)

Antiviral Effects of Clinically-Relevant Interferon-α and Ribavirin Regimens against Dengue Virus in the Hollow Fiber Infection Model (HFIM)

Viruses, 2018-06, Vol.10 (6), p.317

2018

Volltextzugriff (PDF)

1 – 25 von 260

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(254)
Mit Volltextzugriff
(229)

Publikationsform

Artikel
(260)

Sprache

Englisch
(260)

Erscheinungsjahr

n.n

Thema

Science & Technology
(209)
Life Sciences & Biomedicine
(205)
Humans
(164)
Microbiology
(153)
Biological And Medical Sciences
(129)
Medical Sciences
(127)
Pharmacology & Pharmacy
(123)
Pharmacology. Drug Treatments
(106)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(99)
Infectious Diseases
(75)
Female
(70)
Microbial Sensitivity Tests
(70)
Male
(68)
Adult
(53)
Animals
(52)
Anti-Bacterial Agents - Pharmacokinetics
(48)
Pharmacology
(45)
Models, Biological
(43)
Immunology
(39)
Middle Aged
(39)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'

Relationship between Initial Vancomycin Concentration-Time Profile and Nephrotoxicity among Hospitalized Patients

Are Vancomycin Trough Concentrations Adequate for Optimal Dosing?

Dosing Regimen Matters: the Importance of Early Intervention and Rapid Attainment of the Pharmacokinetic/Pharmacodynamic Target

Piperacillin-Tazobactam for Pseudomonas aeruginosa Infection: Clinical Implications of an Extended-Infusion Dosing Strategy

Rational design of a new antibiotic class for drug-resistant infections

Pharmacokinetics-Pharmacodynamics of Antimicrobial Therapy: It's Not Just for Mice Anymore

Daptomycin Exposure and the Probability of Elevations in the Creatine Phosphokinase Level: Data from a Randomized Trial of Patients with Bacteremia and Endocarditis

Analysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculosis

Why Molnupiravir Fails in Hospitalized Patients

Polymyxin Susceptibility Testing and Interpretive Breakpoints: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST)

Concentration-Dependent Mycobacterium tuberculosis Killing and Prevention of Resistance by Rifampin

Back to the Future: Using Aminoglycosides Again and How to Dose Them Optimally

Conserving antibiotics for the future: New ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective

Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update

L-Thyroxine vs. 3,5,3'-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase

Selection of a Moxifloxacin Dose That Suppresses Drug Resistance in Mycobacterium tuberculosis, by Use of an In Vitro Pharmacodynamic Infection Model and Mathematical Modeling

Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit Considerations

Pharmacodynamics of Caspofungin in a Murine Model of Systemic Candidiasis: Importance of Persistence of Caspofungin in Tissues to Understanding Drug Activity

Pharmacokinetic-Pharmacodynamic Considerations in the Design of Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia Studies: Look before You Leap

Quinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae

Combination Therapy with UV-4B and Molnupiravir Enhances SARS-CoV-2 Suppression

Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy

Relationship between Fluoroquinolone Area under the Curve:Minimum Inhibitory Concentration Ratio and the Probability of Eradication of the Infecting Pathogen, in Patients with Nosocomial Pneumonia

Antiviral Effects of Clinically-Relevant Interferon-α and Ribavirin Regimens against Dengue Virus in the Hollow Fiber Infection Model (HFIM)

Suchergebnisse filtern